Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 2018

View Archived Issues

Mir-425 expression levels guide treatment choice in acute myeloid leukemia

NIH grant to support advancement of heroin vaccine OPNT-005

Tesaro opens phase III study of platinum-based therapy with TSR-042 and niraparib in ovarian cancer

NeuroBo Pharmaceuticals set to advance two lead candidates

First proof-of-concept data on IB-MS in patients with inactive PrMS

Anaeropharma and Chugai sign collaborative research agreement in oncology

FDA approves Dupixent as add-on maintenance therapy for asthma

MacroGenics studies MGD-014 in patients with HIV infection on suppressive ART

Temple University patents serotonin 5-HT7 receptor ligands

New phase I trial investigates TRPH-222 in relapsed or refractory B-cell lymphoma

New phase II trial explores use of AC-203 for inherited epidermolysis bullosa

Matrix metalloproteinase inhibitor from Iproteos may hinder epileptogenesis

Arbutus Biopharma divulges new compounds for HBV infection

Merck Sharp & Dohme enrolling patients in phase I study of MK-8583 for HIV-1

Roche presents bacterial DNA gyrase and/or topoisomerase IV inhibitors

Takeda Pharmaceutical and Scohia Pharma patent NFE2-related factor 2 activators

Celgene starts phase III study of bb-2121 in relapsed and refractory multiple myeloma

Biohaven begins phase I study with intranasal third-generation CGRP receptor antagonist for migraine

Merck & Co. discloses new IDO1 inhibitors

Researchers discover possible gene causative of melorheostosis

TAT therapy with [225Ac]RPS-074 effective in prostate cancer model

ESMO 2018: Putting all your eggs in one basket the best way towards sarcoma progress

Researchers find TAF1 to be highly involved in neurodevelopment

The SLCO1B locus is downregulated in alcohol-associated chronic pancreatitis

First clinical data presented at ESMO for the GITR agonist MEDI-1873

LPS-induced inflammation affects uptake of PD-L1 tracer in vivo

AF-3581 demonstrates efficacy in animal models of mood disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...